These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8678501)

  • 21. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
    Tanimura S; Banba J; Tomoyasu H; Masaki M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer].
    Fujii M; Ohno Y; Tokumaru Y; Imanishi Y; Kanke M; Kanzaki J
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1095-101. PubMed ID: 9239162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy.
    Baltzer L; Kris MG; Tyson LB; Rigas JR; Vreeland F; Pisters KM
    Cancer; 1993 Nov; 72(9):2695-9. PubMed ID: 8402492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A comparative study of the effect of granisetron and a combination of granisetron plus steroids on cancer chemotherapy induced emesis].
    Nukariya N; Nakarai I; Kobayashi H; Koizumi W; Komatsu H; Uchiyama T; Yamaguchi T; Taira O; Minato K; Futatsugi K
    Gan To Kagaku Ryoho; 1995 Oct; 22(12):1821-9. PubMed ID: 7574816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of diazepam on delayed nausea and vomiting caused by anticancer agents].
    Tong FZ; Zhang JQ; Qiao XM; Mao YC; Meng FY; Liu HJ; Hui S; Zhu FX; Shu W; Hong J
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):391-5. PubMed ID: 9492833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Multi-drug antiemetic treatment and effect of treatment duration of concurrent steroids--for complete control of chemotherapy-induced nausea/vomiting in gynecological cancer].
    Fujii T; Nakata N; Shiroyama Y; Sawasaki T; Tanimoto H; Shigemasa K; Kioka H; Naito H
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2245-52. PubMed ID: 9422069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Gastrointestinal toxicity induced by anticancer drugs--including new antiemetic drugs].
    Sampi K; Taguchi T
    Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):922-8. PubMed ID: 2140498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-controlled antiemesis for cancer chemotherapy-induced nausea and vomiting.
    Wilder-Smith CH; Schuler L; Osterwalder B; Naji P; Senn HJ
    J Pain Symptom Manage; 1990 Dec; 5(6):375-8. PubMed ID: 2269804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formulation and in vitro/in vivo correlation of a drug-in-adhesive transdermal patch containing azasetron.
    Sun L; Cun D; Yuan B; Cui H; Xi H; Mu L; Chen Y; Liu C; Wang Z; Fang L
    J Pharm Sci; 2012 Dec; 101(12):4540-8. PubMed ID: 22972714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of granisetron in preventing emesis due to anti-cancer drug (CDDP) administration pulmo-mediastinal malignancies--comparison of simultaneous infusion with the conventional method of administration].
    Nakahara K; Minami M; Yasumitsu T; Ikeda M; Ohta M; Nakamura K; Akashi A; Kido T
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):571-6. PubMed ID: 9530364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of clinical effects between granisetron alone and combination of granisetron and methylprednisolone against the nausea and vomiting induced by CDDP chemotherapy--comparative study by the cross-over trial. University of Tsukuba Antiemetics Study Group].
    Uchida K; Akaza H; Shimazui T; Kikuchi K; Manabe F; Iwasaki A; Ishikawa S; Noguchi R; Otani M; Hattori K; Kondo F; Nishijima Y; Sato K; Koiso K; Hinotsu S
    Gan To Kagaku Ryoho; 1996 Jan; 23(1):81-6. PubMed ID: 8546475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Usefulness of alprazolam in controlling cisplatin-induced emesis].
    Mori K; Saitoh Y; Tominaga K; Yokoi K; Miyazawa N
    Gan To Kagaku Ryoho; 1991 Apr; 18(4):631-5. PubMed ID: 1849392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The control of chemotherapy-induced nausea and vomiting].
    Shinkai T; Saijo N; Sawamura N; Funaki U; Takahashi S; Yokoyama S; Fujita J; Futami H; Sasaki Y; Shimizu E
    Gan No Rinsho; 1985 Jun; 31(7):779-91. PubMed ID: 3897622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.
    Harman GS; Omura GA; Ryan K; Hainsworth JD; Cramer MB; Hahne WF
    Cancer Chemother Pharmacol; 1996; 38(4):323-8. PubMed ID: 8674154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.
    Mitchell PL; Evans BD; Allan SG; Forgeson GV; Mak D; Neave L; Humm G; Langley G; Dickson D; Harvey VJ
    N Z Med J; 1992 Mar; 105(929):73-5. PubMed ID: 1532054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.